A distinct natural killer (NK) cell subset, termed CLL_NK, is a precursor to effector NK phenotypes and serves as a critical immunologic marker in chronic lymphocytic leukemia (CLL), offering ...

The best treatment strategy for CLL, including the choice between monotherapy and combination therapies, should be determined on a case-by-case basis, considering the patient's individual ...

This distinct elevation suggests a more aggressive CLL subtype and a decrease in both treatment-free and overall survival rates, irrespective of other prognostic markers. 2.

But IGHV is just one piece of the puzzle, Tausch added. More than 200 genetic drivers have been identified in CLL. Roughly 90% of cases harbor at least one gene mutation or chromosomal aberration ...

Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) are types of slow-growing cancers that affect a type of white blood cell called a lymphocyte.Lymphocytes are cells that help ...

“By partnering with CLL Society for the Test Before Treat campaign, we hope to educate people living with CLL on the importance of biomarker testing and how it can help chart a course for better ...

HOUSTON — Bruton's tyrosine kinase inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib have revolutionized the treatment of chronic lymphocytic leukemia (CLL). But should patients take ...

Chronic Lymphocytic Leukemia (CLL) CLL is the most prevalent type of leukemia in adults, with over 100,000 new cases globally in 2019. 2 Although some people with CLL may not experience any ...

Extended ibrutinib and venetoclax therapy improves outcomes in R/R CLL, with a 40% complete response rate and high survival rates. A six-month ibrutinib lead-in reduces tumor burden and tumor lysis ...